# EDAP to Showcase Ablatherm(R) HIFU Data at 4th International Symposium on Focal Therapy & Imaging in Prostate & Kidney Cancer

LYON, France, May 25, 2011 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced two abstracts supporting the Ablatherm® High Intensity Focused Ultrasound's (HIFU) efficacy for the treatment of localized prostate cancer will be featured at the 4th International Symposium on Focal Therapy & Imaging in Prostate & Kidney Cancer, held on May 25 — 27, 2011 in Amsterdam, Netherlands. EDAP will feature its Ablatherm-HIFU technology at its booth.

Marc Oczachowski, Chief Executive Officer of EDAP TMS, stated, "We are pleased that two poster presentations by leading European urologists that pertain to Ablatherm-HIFU will be presented in Session 5 moderated by Drs. Stefan Thuroff and Ulrich Witzsch. We believe our robotic ultrasound technology is well positioned to address the promising focal approach of prostate cancer. Ablatherm-HIFU offers the required flexibility, repeatability, multimodality and reproducibility in the treatment of localized prostate cancer while actively controlling the disease and preserving patient quality of life.

"The conference will be a major platform to address the advantages of focal therapy in the treatment of prostate patients which are being diagnosed earlier and seek a less invasive treatment that allows them to maintain their lifestyle."

**Scientific Session Highlights:**

**Date/Time:** Thursday, May, 26, 4:15 PM

**Abstract:** Hemi-ablation with HIFU

**Author:** Dr. Sebastin Crouzet, Edouard Herriott Hospital, Lyon, France

**Date/Time:** Thursday, May, 26, 4:30 PM

**Abstract:** How to interpret PSA changes after Focal Therapy?

**Author:** Dr. Roman Ganzer, Regensburg University, Regensburg, Germany

### About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA, the ENLIGHT U.S. clinical study. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit *http://www.edap-tms.com, and http://www.hifu-planet.com.*

### Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans, the conclusiveness of the results of and success of its Ablatherm-HIFU clinical trials and expectations regarding the IDE submission to and approval by the FDA of the Ablatherm-HIFU device. Such statements are based on management's current expectations and are subject to a number of uncertainties, including the uncertainties of the regulatory process, and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.

CONTACT: Company Contact:

Blandine Confort

Investor Relations / Legal Affairs

+33 4 72 15 31 72

bconfort@edap-tms.com

Media/Investors:

Kim Muscara/Stephanie Carrington

646-536-7011/7017

kmuscara@theruthgroup.com

scarrington@theruthgroup.com

Source: EDAP TMS SA